Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Recombinant cancer therapeutic cytokine
US9951114B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9951114-B2 |
| Application number | US-201414895138-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 4, 2014 |
| Priority date | Jun 4, 2013 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.
First claim
Opening claim text (preview).
We claim: 1. A recombinant cytokine comprising: i) a fragment of MDA-7/IL-24 that has antitumor activity and interacts with MDA-7/IL-24 receptors on the surface of cancer cells; and ii) a heterologous secretory leader sequence, wherein: a) said heterologous secretory leader sequence comprises SEQ ID NO: 3, or b) said recombinant cytokine comprises SEQ ID NO: 5. 2. The recombinant cytokine of claim 1 , wherein said fragment of MDA-7/IL-24 comprises SEQ ID NO: 1.
Assignees
Inventors
Classifications
- C07K14/54Primary
Interleukins [IL] · CPC title
- C07K14/5428Primary
IL-10 · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
containing a signal for localisation to secretory granules (for exocytosis) · CPC title
Viral vectors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9951114B2 cover?
- Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 recept…
- Who is the assignee on this patent?
- Univ Virginia Commonwealth
- What technology area does this patent fall under?
- Primary CPC classification C07K14/54. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).